Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03778931




Registration number
NCT03778931
Ethics application status
Date submitted
3/12/2018
Date registered
19/12/2018
Date last updated
30/10/2024

Titles & IDs
Public title
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
Scientific title
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Secondary ID [1] 0 0
RAD1901-308
Universal Trial Number (UTN)
Trial acronym
EMERALD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Elacestrant
Treatment: Drugs - Standard of Care

Experimental: Elacestrant - Subjects in Arm 1 will receive elacestrant

Active comparator: Standard of Care (SoC) - Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)


Treatment: Drugs: Elacestrant
400 mg/day once daily oral dosing

Treatment: Drugs: Standard of Care
* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle
* Anastrozole 1 mg/day on a continuous dosing schedule
* Letrozole: 2.5 mg/day on a continuous dosing schedule
* Exemestane: 25 mg/day on a continuous dosing schedule
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival in ESR1-mut Subjects
Timepoint [1] 0 0
From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
Primary outcome [2] 0 0
Progression-free Survival in All Subjects
Timepoint [2] 0 0
From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)
Secondary outcome [1] 0 0
Overall Survival in ESR1-mut Subjects
Timepoint [1] 0 0
From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months)
Secondary outcome [2] 0 0
Overall Survival in All Subjects
Timepoint [2] 0 0
From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months)

Eligibility
Key inclusion criteria
Critical

1. Subjects with proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy.
2. Subjects must be appropriate candidates for endocrine monotherapy
3. Subjects must have measurable disease or bone only disease
4. Female or male subjects age = 18 years; female subjects must be postmenopausal women and male subjects must not allow pregnancy with their sperm (abstain, do not donate sperm, etc).
5. Subjects must have ER+ and HER2- tumor status
6. Subjects must have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet additional previous treatment criteria.
7. Subjects must have received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (AI) for advanced/metastatic breast cancer (mBC).
8. Subjects may have received no more than one line of chemotherapy in the advanced/metastatic setting.

Critical
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Prior treatment with elacestrant or other investigational selective estrogen receptor degrader (SERD) or ER antagonist (D-0502, GDC-0810, GDC- 0927, GDC-9545, G1T-48, LSZ102, AZD9496, SAR439859, ZN-c5, H3B-6545, bazedoxifene, lasofoxifene).
2. Prior anticancer or investigational drug treatment within the following windows:

1. Fulvestrant treatment < 42 days before first dose of study drug
2. Any endocrine therapy < 14 days before first dose of study drug
3. Chemotherapy < 21 days before first dose of study drug
4. Any investigational anti-cancer drug therapy < 28 days or five half-lives (whichever is shorter) before the first dose of study drug. Enrollment of subjects whose most recent therapy was an investigational agent should be discussed with the Sponsor
5. Bisphosphonates or RANKL inhibitors initiated or dose changed < 3 months prior to first dose of study drug
3. Presence of symptomatic visceral disease as defined in protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/05/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/08/2024
Sample size
Target
Accrual to date
Final
478
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Mater Misericordiae Ltd Mater Cancer Care Centre - Brisbane
Recruitment hospital [2] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [3] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [4] 0 0
Macarthur Cancer Therapy - Campbelltown
Recruitment postcode(s) [1] 0 0
4101 - Brisbane
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
4575 - Birtinya
Recruitment postcode(s) [4] 0 0
2560 - Campbelltown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Mississippi
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
New Jersey
Country [23] 0 0
United States of America
State/province [23] 0 0
New Mexico
Country [24] 0 0
United States of America
State/province [24] 0 0
New York
Country [25] 0 0
United States of America
State/province [25] 0 0
North Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Ohio
Country [27] 0 0
United States of America
State/province [27] 0 0
Oregon
Country [28] 0 0
United States of America
State/province [28] 0 0
Pennsylvania
Country [29] 0 0
United States of America
State/province [29] 0 0
South Carolina
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Utah
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
United States of America
State/province [35] 0 0
Wisconsin
Country [36] 0 0
Argentina
State/province [36] 0 0
Buenos Aires
Country [37] 0 0
Argentina
State/province [37] 0 0
Ciudad Autonoma De Buenos Aires
Country [38] 0 0
Argentina
State/province [38] 0 0
Ciudad Autónoma De Buenos Aires
Country [39] 0 0
Argentina
State/province [39] 0 0
Ciudad Autónoma De Buenos Aire
Country [40] 0 0
Argentina
State/province [40] 0 0
Santa Fe
Country [41] 0 0
Argentina
State/province [41] 0 0
Tucumán
Country [42] 0 0
Argentina
State/province [42] 0 0
Córdoba
Country [43] 0 0
Argentina
State/province [43] 0 0
La Rioja
Country [44] 0 0
Austria
State/province [44] 0 0
Oberösterreich
Country [45] 0 0
Austria
State/province [45] 0 0
Steiermark
Country [46] 0 0
Austria
State/province [46] 0 0
Tirol
Country [47] 0 0
Belgium
State/province [47] 0 0
Antwerpen
Country [48] 0 0
Belgium
State/province [48] 0 0
Brussels Capital Region
Country [49] 0 0
Belgium
State/province [49] 0 0
Hainaut
Country [50] 0 0
Belgium
State/province [50] 0 0
Luxembourg
Country [51] 0 0
Belgium
State/province [51] 0 0
Oost-Vlaanderen
Country [52] 0 0
Belgium
State/province [52] 0 0
Vlaams Brabant
Country [53] 0 0
Belgium
State/province [53] 0 0
West-Vlaanderen
Country [54] 0 0
Belgium
State/province [54] 0 0
Kortrijk
Country [55] 0 0
Belgium
State/province [55] 0 0
Namur
Country [56] 0 0
Belgium
State/province [56] 0 0
Ottignies
Country [57] 0 0
Canada
State/province [57] 0 0
Ontario
Country [58] 0 0
Canada
State/province [58] 0 0
Quebec
Country [59] 0 0
Canada
State/province [59] 0 0
Québec
Country [60] 0 0
Denmark
State/province [60] 0 0
South Denmark
Country [61] 0 0
Denmark
State/province [61] 0 0
Zeeland
Country [62] 0 0
Denmark
State/province [62] 0 0
Aalborg
Country [63] 0 0
Denmark
State/province [63] 0 0
Odense
Country [64] 0 0
France
State/province [64] 0 0
Bas-Rhin
Country [65] 0 0
France
State/province [65] 0 0
Calvados
Country [66] 0 0
France
State/province [66] 0 0
Haute-Garonne
Country [67] 0 0
France
State/province [67] 0 0
Indre-et-Loire
Country [68] 0 0
France
State/province [68] 0 0
Nord
Country [69] 0 0
France
State/province [69] 0 0
Puy-de-Dôme
Country [70] 0 0
France
State/province [70] 0 0
Rhône
Country [71] 0 0
France
State/province [71] 0 0
Caen
Country [72] 0 0
France
State/province [72] 0 0
Dijon
Country [73] 0 0
France
State/province [73] 0 0
Montpellier
Country [74] 0 0
France
State/province [74] 0 0
Paris
Country [75] 0 0
France
State/province [75] 0 0
Saint-Priest-en-Jarez
Country [76] 0 0
France
State/province [76] 0 0
Île-de-France
Country [77] 0 0
Greece
State/province [77] 0 0
Achaïa
Country [78] 0 0
Greece
State/province [78] 0 0
Attiki
Country [79] 0 0
Greece
State/province [79] 0 0
Larisa
Country [80] 0 0
Greece
State/province [80] 0 0
Thessaloniki
Country [81] 0 0
Hungary
State/province [81] 0 0
Baranya
Country [82] 0 0
Hungary
State/province [82] 0 0
Hajdú-Bihar
Country [83] 0 0
Hungary
State/province [83] 0 0
Jász-Nagykun-Szolnok
Country [84] 0 0
Hungary
State/province [84] 0 0
Szabolcs-Szatmár-Bereg
Country [85] 0 0
Hungary
State/province [85] 0 0
Budapest
Country [86] 0 0
Ireland
State/province [86] 0 0
Cork
Country [87] 0 0
Ireland
State/province [87] 0 0
Dublin
Country [88] 0 0
Ireland
State/province [88] 0 0
Sligo
Country [89] 0 0
Ireland
State/province [89] 0 0
Waterford
Country [90] 0 0
Israel
State/province [90] 0 0
HaMerkaz
Country [91] 0 0
Israel
State/province [91] 0 0
Jerusalem
Country [92] 0 0
Israel
State/province [92] 0 0
Kfar-Saba
Country [93] 0 0
Israel
State/province [93] 0 0
Nahariya
Country [94] 0 0
Israel
State/province [94] 0 0
Petah Tikva
Country [95] 0 0
Israel
State/province [95] 0 0
Tel-Aviv
Country [96] 0 0
Israel
State/province [96] 0 0
Zerifin
Country [97] 0 0
Italy
State/province [97] 0 0
Forli-Cesena
Country [98] 0 0
Italy
State/province [98] 0 0
Milano
Country [99] 0 0
Italy
State/province [99] 0 0
Monza E Brianza
Country [100] 0 0
Italy
State/province [100] 0 0
Bologna
Country [101] 0 0
Italy
State/province [101] 0 0
Cremona
Country [102] 0 0
Italy
State/province [102] 0 0
Genova
Country [103] 0 0
Italy
State/province [103] 0 0
Meldola
Country [104] 0 0
Italy
State/province [104] 0 0
Modena
Country [105] 0 0
Italy
State/province [105] 0 0
Novara
Country [106] 0 0
Italy
State/province [106] 0 0
Parma
Country [107] 0 0
Italy
State/province [107] 0 0
Pavia
Country [108] 0 0
Italy
State/province [108] 0 0
Perugia
Country [109] 0 0
Italy
State/province [109] 0 0
Pisa
Country [110] 0 0
Italy
State/province [110] 0 0
Roma
Country [111] 0 0
Italy
State/province [111] 0 0
Udine
Country [112] 0 0
Korea, Republic of
State/province [112] 0 0
Seoul Teugbyeolsi
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Goyang
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Incheon
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Seongnam-si
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Seoul
Country [117] 0 0
Portugal
State/province [117] 0 0
Coimbra
Country [118] 0 0
Portugal
State/province [118] 0 0
Guimarães
Country [119] 0 0
Portugal
State/province [119] 0 0
Lisboa
Country [120] 0 0
Portugal
State/province [120] 0 0
Porto
Country [121] 0 0
Spain
State/province [121] 0 0
Alicante
Country [122] 0 0
Spain
State/province [122] 0 0
Andalucía
Country [123] 0 0
Spain
State/province [123] 0 0
Canarias
Country [124] 0 0
Spain
State/province [124] 0 0
Illes Balears
Country [125] 0 0
Spain
State/province [125] 0 0
Madrid
Country [126] 0 0
Spain
State/province [126] 0 0
Navarra
Country [127] 0 0
Spain
State/province [127] 0 0
Pontevedra
Country [128] 0 0
Spain
State/province [128] 0 0
Barcelona
Country [129] 0 0
Spain
State/province [129] 0 0
Sevilla
Country [130] 0 0
Spain
State/province [130] 0 0
Valencia
Country [131] 0 0
United Kingdom
State/province [131] 0 0
England
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Hampshire
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Kent
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Somerset
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Cardiff
Country [136] 0 0
United Kingdom
State/province [136] 0 0
London

Funding & Sponsors
Primary sponsor type
Other
Name
Stemline Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .
Trial website
https://clinicaltrials.gov/study/NCT03778931
Trial related presentations / publications
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garcia Saenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortes J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. Erratum In: J Clin Oncol. 2023 Aug 10;41(23):3962. doi: 10.1200/JCO.23.01239.
Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol. 2019 Oct;15(28):3209-3218. doi: 10.2217/fon-2019-0370. Epub 2019 Aug 20.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03778931